


In the Claims:

Please amend claim 16 as follows:

16. A compound represented by the following structural formula:



or physiologically acceptable salts thereof, wherein:

ring A is substituted with suitable substituents or unsubstituted;

Q is  $-N=$  or  $-CR^2=$ ;

X is S, O or  $NOR^3$ ;

Y is  $-S-$ ,  $-SO-$  or  $-SO_2-$

$R^2$  is  $-H$  or a substituent;

$R^3$  is  $-H$  or  $-C(O)R^4$ ;


$R^4$  is a substituted with suitable substituents or unsubstituted aliphatic or aromatic group;

n is 0 or 1; and wherein

when X is S or  $NOR^3$ , R is an optionally substituted with suitable substituents aromatic or aralkyl group and  $R^1$  is hydrogen or a substituted with suitable substituents or unsubstituted aliphatic group;


when X is O and n is 0,  $R^1$  is hydrogen or a substituted with suitable substituents or unsubstituted aliphatic group and R is a substituted with suitable substituents or unsubstituted aromatic or aralkyl group, provided that R is not 2-thienyl, benzoxadiazolyl, 4-oxo-4H-1-benzopyran-3-yl, 6-chloro-4-oxo-4H-1-benzopyran-3-yl, 6-methyl-4-oxo-4H-1-benzopyran-3-yl, 6-acetyloxy-4-oxo-4H-1-benzopyran-3-yl, naphthyl, 3-furanyl, 2-furanyl, 2-yrityl, 3-pyridinyl, 4-pyridyl, 2,4-dichlorophenyl, 2,6-dichlorophenyl, 4-acetyloxy-3-methoxyphenyl, 3,5-dimethoxyphenyl, 3,4,5-

trimethoxyphenyl, 3,5-*t*-butyl-4-hydroxyphenyl, 3,5-*i*-propyl-4-hydroxyphenyl, 3-(2-hydroxyphenyl)-1H-pyrazol-4-yl, 3-(5-chloro-2-hydroxyphenyl)-1H-pyrazol-4-yl, or



CI where R<sup>14</sup> is H, *p*-F, *o*-Cl, *p*-Cl, *p*-Br, *m*-Br, *o*-CH<sub>3</sub>, *p*-CH<sub>3</sub>, *p*-OCH<sub>2</sub>CH<sub>3</sub>, -O-Benzyl, CF<sub>3</sub>, phenyl, -OCH<sub>3</sub>, -O-phenyl, NO<sub>2</sub>, -OC(O)CH<sub>3</sub>, OCH<sub>2</sub>C(O)C<sub>2</sub>H<sub>5</sub>, -OCH<sub>2</sub>C(O)NHNH<sub>2</sub>, *p*-(-O-(CH<sub>2</sub>)<sub>5</sub>-N(CH<sub>3</sub>)<sub>2</sub>), *p*-(-O-(CH<sub>2</sub>)<sub>3</sub>-N(n-C<sub>3</sub>H<sub>7</sub>)<sub>2</sub>), *p*-(3-piperidin-1-yl-propan-1-oxy), *m*-(2-morpholin-4-yl-ethan-1-oxy), or *m*-(4-(4-ethyl-piperazin-1-yl)-butan-1-oxy); and

when X is O and n is 1, R<sup>1</sup> is H or a substituted with suitable substituents or unsubstituted aliphatic group and R is a substituted with suitable substituents or unsubstituted aromatic or aralkyl group, provided that R is no 4-nitro-2-methoxyphenyl, 4-methoxy-2-nitrophenyl, 4-chloro-2-nitrophenyl, 2,5-dichlorophenyl, or



where R<sup>15</sup> is H, Cl, *p*-NO<sub>2</sub>, *o*-NO<sub>2</sub>, *p*-OCH<sub>3</sub>, *o*-CO<sub>2</sub>H, CH<sub>3</sub> or CF<sub>3</sub>.

---